The updated indication allows clinicians to prescribe upadacitinib to patients who have received at least one approved systemic therapy when tumor necrosis factor blockers are clinically inadvisable. Previously, upadacitinib was indicated only for adults with moderately to severely active ulcerative colitis or Crohn disease who had an inadequate response or intolerance to one or more TNF blockers. "This label update gives healthcare providers the option to prescribe RINVOQ for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician," Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, said in a press release. Upadacitinib is a JAK inhibitor discovered and developed by AbbVie. The drug inhibits cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 in human leukocyte cellular assays.